Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval
Jun 1, 2018Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market
Toronto, ON, June 1st - 2018 - Apobiologix, a division of Apotex Inc., further bolstered its leadership in Canada’s growing biosimilar market. The company that is focused on the development of biosimilars for global markets, recently received approval from Health Canada for Apobiologix’s latest product addition, LapelgaTM.
The recent Health Canada approval is a noteworthy success for Apobiologix as this is the first-ever pegfilgrastim biosimilar approved in any highly regulated market worldwide.
Apobiologix successfully launched its first product, Grastofil (filgrastim) in Canada in March, 2016. Since that time, Grastofil has delivered significant cost savings to the Canadian healthcare system.
“Biosimilars provide an opportunity for the sustainability of global healthcare systems by increasing competition and reducing costs, and very importantly, giving patients increased access to highly effective and often lifesaving biological drugs,” said Dr. Klaus Martin, President, Apobiologix.
Biosimilars are designed to be similar to an existing biologic drug. Biologic drugs come from living organisms or from their cells and are often made using biotechnology. LapelgaTM encourages the body’s production of white blood cells which helps to fight infection in patients undergoing certain cancer treatments, such as chemotherapy and radiation.
According to Evaluate Pharma 2017 and IMSQuintiles, 2017, IQVIA “2018 and beyond” report, the global biologics market is expected to reach more than $325 billion in 2022 with 13 of 20 top-selling drugs being biologics.
###
Jordan Berman
Global Director, Corporate Communications
Apotex Inc.
Direct: 416-401-7487
Mobile: 647-272-2287
Email
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.